Latest Januvia news
FDA: Common Diabetes Drug Januvia May Contain Traces of Carcinogen
posted August 12th
by modernClinician Editorial Team
by modernClinician Editorial Team
Sitagliptin Stimulates Distal Tubular Natriuresis in T2DM
posted June 9th
by modernClinician Editorial Team
by modernClinician Editorial Team
For patients with type 2 diabetes, the dipeptidyl peptidase-4 inhibitor sitagliptin stimulates distal tubular natriuresis, according to a study published online May 26 in Diabetes Care.
Sitagliptin Has Neutral CV Risk Effect in Elderly With T2DM, CVD
posted January 12th
by modernClinician Editorial Team
by modernClinician Editorial Team
Sitagliptin has a neutral effect on cardiovascular risk among older patients with type 2 diabetes, according to a study published online Jan. 5 in Diabetes Care.
Sitagliptin Not Linked to Higher Fracture Risk in Diabetes
posted September 14th
by modernClinician Editorial Team
by modernClinician Editorial Team
Patients with diabetes often have fractures, but sitagliptin is not associated with increased fracture risk, according to a study published online Sept. 8 in Diabetes, Obesity and Metabolism.
Vascular Burden in Midlife Linked to Increased Risk for Dementia, Death
GLP-1 Receptor Agonists Tied to Increased Risk for Alopecia
Food-Based Support Aids Type 2 Diabetes Outcomes
Hypoglossal Nerve Stimulation May Offer Long-Term Cardiovascular Benefits in OSA
Metformin, Sitagliptin Prolong Normoglycemia Remission in DKA
Vildagliptin, Sitagliptin Have Similar Effects on Incretin